Tibsovo is a first-in-class oral targeted small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (IDH1) designed to decrease accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG), resulting in reduced blast counts and increased percentages of mature myeloid cells in patients with relapsed or refractory acute myeloid leukemia (AML).

If you have a Hayes login, click here to view the full report on the Knowledge Center.